Title : Sacubitril/valsartan (LCZ696) for the treatment of heart failure.

Pub. Date : 2016

PMID : 26642078






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The PARADIGM-HF study, a large outcome trial in heart failure and reduced ejection fraction (HFrEF), has recently shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto , Novartis), still commonly referred to as LCZ696, compared to ACE-inhibitor therapy, possibly leading us to a new era for heart failure (HF) treatment. Valsartan angiotensin I converting enzyme Homo sapiens